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Dr Cozzolino and Dr Brancaccio raise the point that,
contrary to their expectations, we reported extraosseous
calcifications in uremic rats treated with paricalcitol. This is
a valid concern which we would like to address and, at the
same time, discuss two more articles on this subject which
were published almost simultaneously to our paper.2,3
Cardus et al.2 have studied, both in vitro and in vivo, the
differential effects of calcitriol and paricalcitol on vascular
calcifications. Contrary to the assertion of Dr Cozzolino
and Dr Brancaccio, the in vivo results reported by Cardus
et al. are quite similar to the results reported in our paper.
The aortic image with calcified foci after treatment with
paricalcitol presented by Cardus et al. is almost identical to
the aortic image reported in our paper. Moreover, Cardus
et al. reported an increase in aortic calcium content in rats
treated with paricalcitol, which in fact is higher than what
we found.
In their paper, Mizobuchi et al.3 showed that neither
aortic calcium content nor von Kossa staining increased in
uremic rats after treatment with paricalcitol. These authors
induced uremia with the same model reported in our paper
(5/6 nephrectomized rats on a high phosphorus diet).
However, a careful reading of their study reveals several
interesting differences: (1) the rats treated with paricalcitol
by Mizobuchi et al. were less uremic (creatinine: 1.1±0.1 mg
per 100 ml) than the rats in our study (creatinine:
1.8±0.9 mg per 100 ml); (2) the rats in the study of
Mizobuchi et al. also had less severe hyperparathyroidism
(PTH: 72±15 vs 191±42 pg/ml in our study); and (3) in the
rats in which they report the biochemical values referenced
above, Mizobuchi et al. administered a lower dose of
paricalcitol, 0.16 vs 0.24 lg/kg in our study. In conclusion,
these rats were less uremic, had a lesser degree of HPT and,
consequently, required a lower dose of paricalcitol to control
secondary HPT than in our study. Mizobuchi et al. also
studied a higher dose of paricalcitol (0.24 lg/kg) but they do
not provide creatinine or PTH values of these rats and thus
it is difficult to compare their results.
Dr Cozzolino and Dr Brancaccio suggest that paricalcitol
exerts a lower affinity for the vitamin D receptor in bone.
However, it is our belief that the literature suggests that
paricalcitol is instead a less potent molecule than calcitriol,
highlighted by the differences in dosing suggested in the
prescribing information. In addition, they mention studies
suggesting that paricalcitol provides a survival benefit in
dialysis patients with respect to untreated patients4 and to
those treated with calcitriol.5 We would like to point out that
these are observational studies, with all of the limitations
inherent in this type of study design, whose conclusions are
not supported by all reports,6 including a recently published
meta analysis by Palmer et al.7
We believe that there is accumulating evidence showing
that paricalcitol induces less vascular calcification than
other vitamin D analogs. In fact, under certain conditions,
paricalcitol may be able to control secondary hyperpar-
athyroidism without inducing calcifications, as shown by
Mizobuchi et al. However, when uremia is severe the doses
of paricalcitol needed to control secondary HPT result in
extraskeletal calcifications whereas calcimimetics are able
to control secondary HPT without inducing calcifications.
Finally, an important point is that these two treatments are
not exclusive since, as reported in our paper, when used in
combination with paricalcitol AMG 641 provides excellent
control of secondary HPT and diminishes paricalcitol-
mediated vascular calcification. In fact, the combined use
of paricalcitol and calcimimetics may allow the reduction
of the dose of paricalcitol needed to achieve an effective
control of severe HPT and thus prevent the development of
calcifications.
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Secondary hyperparathyroidism is
associated with higher mortality
in men with moderate to severe
chronic kidney disease
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To the Editor: We were interested to read the study of
increased mortality in chronic kidney disease patients with
secondary hyperparathyroidism by Kovesdy et al.1 They
reported that secondary hyperparathyroidism is indepen-
dently associated with higher mortality rates in chronic
kidney disease patients not yet on dialysis. We have some
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objections about the risk factor of mortality in chronic
kidney disease patients. Proteinuria that is defined as urinary
protein excretion of greater than 150 mg/day is a widely
available and cost-effective marker of cardiovascular risk.2
There is strong evidence that proteinuria is associated with an
increase in adverse clinical outcomes, including increased
mortality in not only chronic kidney disease patients but also
subjects with a normal glomerular filtration rate.3,4 However,
they did not include proteinuria either in univariate or
multivariate analysis in their study.1 It is also important to
note that due to the intraindividual variability of urinary
albumin excretion, the estimated risk of death associated with
microalbuminuria may be underestimated.3 In a study by
Klausen et al.3 it is clearly reported that microalbuminuria is
a strong determinant of coronary heart disease and death
independently of age, sex, hypertension, diabetes mellitus,
renal function, and lipids. Similarly in another study by
Culleton et al.4 of 2,582 people, proteinuria is shown to be an
independent significant risk factor for all-cause mortality in
both genders.
In the study by Kovesdy et al.,1 patients were divided into
four groups according to their intact parathyroid hormone
levels. It is clearly seen that there is a statistically significant
difference between those groups for proteinuria levels. This
may be the reason or at least one of the contributing factors
for increased mortality in the high parathyroid hormone
group. Increased parathyroid hormone may be a major risk
factor but it is obvious that proteinuria is also statistically
significantly high in high parathyroid hormone groups. In
adjustment analysis, they took age, race, body mass index,
smoking, comorbidities, estimated growth factor receptor,
serum calcium, phosphorus, albumin and cholesterol levels,
and the use of activated vitamin D and calcium-containing
medications but not proteinuria, which is known to be one of
the most important independent risk factors in end stage
renal failure development and mortality. In multivariable
analysis, proteinuria should be taken into consideration.
Finally, in our opinion, proteinuria is an important factor
increasing mortality in those patients and this study should
be reconsidered in this aspect.
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We appreciate the interest shown by Kanbay et al. in
our paper.1 They question our decision to exclude
proteinuria from multivariable analyses that examined
the association between serum intact parathyroid hormone
(PTH) level and mortality in patients with nondialysis-
dependent chronic kidney disease stages 3–5. The decision
to exclude proteinuria was based on the following
considerations: first, proteinuria does not satisfy criteria
for a confounder in the association between PTH and
mortality, because it has no independent effect on serum
PTH concentration, even though it might affect mortality.2
Whereas Kanbay et al. are correct in pointing out a
discrepancy in the magnitude of proteinuria among our
patients at different PTH levels, this finding in itself
does not necessarily make proteinuria a confounder.
The said discrepancy can indeed be due to the role of
another independent variable with similar imbalance,
which is also associated with proteinuria, such as the
differences in kidney function and/or blood pressure
among different PTH increments. Second, the decision
not to include proteinuria as a covariate was also driven by
a desire to achieve a more parsimonious multivariable
model, especially as our study population had a relatively
smaller size and a limited number of events. Under these
circumstances including too many covariates can result not
only in less stable summary estimates, but might also
introduce new sources of bias. Finally, including protei-
nuria as a covariate during our sensitivity analyses did not
substantially alter the association between PTH and
mortality.
1. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Secondary
hyperparathyroidism is associated with higher mortality in men with
moderate to severe chronic kidney disease. Kidney Int 2008; 73:
1296–1302.
2. Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc
Nephrol 2006; 1: 1117–1123.
Csaba P. Kovesdy1 and Kamyar Kalantar-Zadeh2
1Salem VA Medical Center, Renal Medicine, Salem, Virginia, USA and 2Harold
Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance,
California
Correspondence: Csaba P. Kovesdy, Salem VA Medical Center,
Renal Medicine, 1970 Roanoke Boulevard, Salem, Virginia 24153, USA.
E-mail: csaba.kovesdy@va.gov
l e t t e r t o t h e e d i t o r
968 Kidney International (2008) 74, 962–973
